
|Videos|June 4, 2021
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals drop in development for treating presbyopia
Advertisement
Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
2
AAOpt 2025: Advances in regenerative medicine for the ocular surface
3
Glaukos’ Epioxa gains FDA nod for non-invasive keratoconus therapy
4
AAOpt 2025: The art and science of scleral lens fitting
5